427 related articles for article (PubMed ID: 20429725)
1. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Dupont J; Jensen HA; Jensen BV; Pfeiffer P
Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Stein A; Arnold D; Thuss-Patience PC; Moehler M; Grothe W; Seufferlein T; Reinacher-Schick A; Geissler M; Hofheinz RD; Schmoll HJ
Acta Oncol; 2014 Mar; 53(3):392-8. PubMed ID: 24024696
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Malik I; Bernal P; Byrd J
Cancer Invest; 2010 Oct; 28(8):833-8. PubMed ID: 20839949
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
[TBL] [Abstract][Full Text] [Related]
10. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M
Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
12. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
[TBL] [Abstract][Full Text] [Related]
13. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Schønnemann KR; Yilmaz M; Andersen M; Pfeiffer P
Acta Oncol; 2011 Jan; 50(1):151-2. PubMed ID: 20843172
[No Abstract] [Full Text] [Related]
14. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
16. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
[TBL] [Abstract][Full Text] [Related]
17. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
[TBL] [Abstract][Full Text] [Related]
18. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Thuss-Patience PC; Hofheinz RD; Arnold D; Florschütz A; Daum S; Kretzschmar A; Mantovani-Löffler L; Bichev D; Breithaupt K; Kneba M; Schumacher G; Glanemann M; Schlattmann P; Reichardt P; Gahn B
Ann Oncol; 2012 Nov; 23(11):2827-2834. PubMed ID: 22734012
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Goel G; Jauhri M; Negi A; Aggarwal S
Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
